These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 31258461)
21. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127 [TBL] [Abstract][Full Text] [Related]
22. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
24. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948 [TBL] [Abstract][Full Text] [Related]
25. Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods. Tarutani A; Arai T; Murayama S; Hisanaga SI; Hasegawa M Acta Neuropathol Commun; 2018 Apr; 6(1):29. PubMed ID: 29669601 [TBL] [Abstract][Full Text] [Related]
27. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Alam M; Mayerhofer A; Schmidt WJ Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427 [TBL] [Abstract][Full Text] [Related]
28. Immunoreactivity of a G protein-coupled l-DOPA receptor GPR143, in Lewy bodies. Goshima Y; Watanabe S; Seki E; Koga M; Masukawa D; Nakamura F; Komori T; Arai N Neurosci Res; 2019 Nov; 148():49-53. PubMed ID: 30590075 [TBL] [Abstract][Full Text] [Related]
29. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524 [TBL] [Abstract][Full Text] [Related]
30. Levodopa (L-DOPA) attenuates endoplasmic reticulum stress response and cell death signaling through DRD2 in SH-SY5Y neuronal cells under α-synuclein-induced toxicity. Song J; Kim BC; Nguyen DT; Samidurai M; Choi SM Neuroscience; 2017 Sep; 358():336-348. PubMed ID: 28687316 [TBL] [Abstract][Full Text] [Related]
31. The concept of alpha-synuclein as a prion-like protein: ten years after. Steiner JA; Quansah E; Brundin P Cell Tissue Res; 2018 Jul; 373(1):161-173. PubMed ID: 29480459 [TBL] [Abstract][Full Text] [Related]
32. Prion-like propagation of α-synuclein in the gut-brain axis. Chen Y; Shao Q; Yuan YH; Chen NH Brain Res Bull; 2018 Jun; 140():341-346. PubMed ID: 29894766 [TBL] [Abstract][Full Text] [Related]
33. The pharmacology of Parkinson's disease: basic aspects and recent advances. Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857 [TBL] [Abstract][Full Text] [Related]
34. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites. Alachkar A; Brotchie JM; Jones OT Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064 [TBL] [Abstract][Full Text] [Related]
35. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Alam M; Schmidt WJ Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640 [TBL] [Abstract][Full Text] [Related]
36. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. Shin JY; Park HJ; Ahn YH; Lee PH J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187 [TBL] [Abstract][Full Text] [Related]
37. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease. Sharma N; Rao SP; Kalivendi SV Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974 [TBL] [Abstract][Full Text] [Related]
38. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease. Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934 [TBL] [Abstract][Full Text] [Related]